CTOs on the Move


 
Valiant Living is a company that offers comprehensive outpatient treatment and recovery services for men and their families, as well as enhanced recovery living environments for men who need a productive transition period after primary treatment.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Ripple

Ripple is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CareVet

CareVet is a veterinary practice management group whose mission is to provide the very best care for pets through a holistic approach to medicine. We focus on five pillars of care: practice legacy, veterinarians, team, patients and community. ...

Focus Diagnostics

Focus Diagnostics is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Focus Diagnostics is based in Cypress, CA. You can find more information on Focus Diagnostics at www.focusdx.com

Delta Regional Medical Center

Delta Regional Medical Center has been committed to serving the citizens of Washington County and the outlying areas since our founding in the 1950s. Over time we have grown and progressed into a state-of-the-art hospital with a number of specialty

Foghorn Therapeutics

More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.